Maze Therapeutics (NASDAQ:MAZE – Free Report) had its price target lifted by HC Wainwright from $60.00 to $110.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Maze Therapeutics’ Q1 2026 earnings at ($0.62) EPS, Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.63) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.57) EPS, FY2027 earnings at ($2.79) EPS, FY2028 earnings at ($0.57) EPS, FY2029 earnings at ($0.04) EPS and FY2030 earnings at $1.00 EPS.
Other equities analysts have also recently issued research reports about the stock. Lifesci Capital upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Wedbush increased their price target on shares of Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research note on Monday, March 16th. Truist Financial assumed coverage on Maze Therapeutics in a research note on Tuesday, March 17th. They issued a “buy” rating and a $68.00 price objective on the stock. Finally, BTIG Research restated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Monday, March 9th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $64.11.
View Our Latest Research Report on Maze Therapeutics
Maze Therapeutics Stock Down 4.2%
Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08.
Insider Activity at Maze Therapeutics
In other news, SVP Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $46.04, for a total value of $230,200.00. Following the completion of the transaction, the senior vice president owned 12,965 shares in the company, valued at approximately $596,908.60. This trade represents a 27.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction on Thursday, January 29th. The stock was sold at an average price of $44.27, for a total transaction of $332,025.00. Following the completion of the transaction, the insider directly owned 10,503 shares of the company’s stock, valued at approximately $464,967.81. This represents a 41.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 245,000 shares of company stock valued at $10,504,792 over the last ninety days.
Hedge Funds Weigh In On Maze Therapeutics
Several institutional investors have recently made changes to their positions in MAZE. Royal Bank of Canada grew its stake in Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after buying an additional 363 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics during the 4th quarter worth about $39,000. Ameritas Investment Partners Inc. lifted its position in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Maze Therapeutics during the fourth quarter valued at about $43,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares in the last quarter.
More Maze Therapeutics News
Here are the key news stories impacting Maze Therapeutics this week:
- Positive Sentiment: HC Wainwright materially raised near‑term EPS estimates across 2026–2029 and boosted FY2030 to $1.00 while maintaining a “Buy” rating and a $110 price target — a strong analyst endorsement that supports upside if development and regulatory paths stay on track. HC Wainwright Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $110.00
- Positive Sentiment: BTIG issued a “Buy” rating, adding further sell‑side support that could attract buyers looking for durable conviction from institutional analysts. Maze Therapeutics (NASDAQ:MAZE) Earns “Buy” Rating from BTIG Research
- Positive Sentiment: Phase 2 HORIZON data for MZE829 showed a clinically meaningful ~35.6% mean reduction in proteinuria (uACR), exceeding the ≥30% threshold cited for regulatory relevance — the fundamental clinical readout supports a pathway toward a pivotal trial. Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
- Neutral Sentiment: Technical metrics show the stock moved into oversold territory after the selloff, and some analysts/technicals argue the decline may have exhausted short‑term sellers — this could set up a technical bounce independent of fundamentals. After Plunging 30.8% in 4 Weeks, Here’s Why the Trend Might Reverse for Maze Therapeutics
- Negative Sentiment: Despite positive efficacy, the market treated the Phase 2 results as “mixed” on endpoints/subgroup/readout detail, triggering a steep selloff that wiped nearly a third of market value — heightened volatility and investor uncertainty remain key near‑term risks. Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data
- Negative Sentiment: A shareholder law firm (Johnson Fistel) has opened an investigation into potential claims related to MAZE disclosures — this introduces legal/PR risk and could prolong downward pressure if it results in litigation or heightened scrutiny. MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel
- Negative Sentiment: Media coverage captured the paradox of “best‑in‑class potential” commentary alongside a sharp post‑readout plunge, amplifying sentiment swings and increasing short‑term trading risk. After ph. 2 readout, analysts herald best‑in‑class potential as stock plummets
Maze Therapeutics Company Profile
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Further Reading
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
